Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
Update of the EuroGuiDerm evidence-based guideline for the treatment of acne-Short version.
СтатьяКлинические рекомендацииНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nast Alexander, Al Wattar Bassel H, Beylot Barry Marie, Brüggemann Holger, Bukvić Mokos Zrinka, Caruana Dawn M, Degitz Klaus, Dessinioti Clio, Dréno Brigitte, Driessen Rieke J B, Gollnick Harald, Hædersdal Merete, Katoulis Alexander, Läuchli Severin, Lambert Julien, Layton Alison M, Micali Giuseppe, Ochsendorf Falk R, Sathyapalan Thozhukat, Stangeland Katarina Zak, Thomsen Simon Francis, Töröcsik Daniel, Pennitz Antonia
Аннотация
This evidence- and consensus-based guideline for the treatment of acne was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. This guideline is an update of the 2016 version. This is a short summary of the full version of the EuroGuiDerm Evidence-based Guideline for the Treatment of Acne. For the complete guideline text, detailed methods report, and comprehensive evidence report, please refer to the online full version. In this targeted update, the guideline group prioritized three key clinical questions considered most relevant for current practice: (a) For which types of acne and patient groups should isotretinoin be recommended versus systemic antibiotics, and with what strength of recommendation? (b) What is the appropriate duration for systemic antibiotic therapy? For which types of acne and patient groups should hormonal treatments and spironolactone be recommended, and with what strength of recommendation? For which types of acne and patient groups should new topical treatments, including trifarotene and clascoterone, be recommended and with what strength of recommendation? Additionally, the updated guideline provides revised recommendations regarding: safety of benzoyl peroxide (BPO), selection of systemic antibiotic therapy, treatment considerations during pregnancy, isotretinoin dosing strategies, and the use of hormonal antiandrogenic contraceptives or other combined hormonal contraceptives, as well as spironolactone. All other aspects remain unchanged from the 2016 guideline.